Literatur

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis. A randomised trial.

In: Lancet 354, S. 635–639.

Weitere Veröffentlichungen:

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis

Weitere Informationen

Potenzial von Escherichia coli Nissle 1917 in der Behandlung des septischen Schocks

Weitere Informationen

NF-KappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917. A novel effect of a probiotic bacterium.

Weitere Informationen

Rembacken, B. J.; Snelling, A. M.; Hawkey, P. M.; Chalmers, D. M.; Axon, A. T. R. (1999): Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis. A randomised trial.